Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were reported to correlate with histological recurrence and antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar results have not been described yet in living donor liver transplant patients.

There is data suggesting slightly inferior outcomes in living donor liver transplants when done for hepatitis C. The investigators postulate that such inferior outcomes may be related to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive similarly unfavorable polymorphism livers from their relatives).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation

NCT00794911

Chronic HCV

COMPLETED NA

Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)

NCT01448915

HIV Infection Hepatitis C

COMPLETED

Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C

NCT02006823

Chronic Hepatitis C

COMPLETED

Transforming the Cascade Of Hepatitis C Care

NCT03226509

Hepatitis C, Chronic

COMPLETED

Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

NCT00871845

Obesity Insulin Resistance Metabolic Syndrome +1 more

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liver transplant recipeints

Patients suffering from chronic hepatitis C that required a living donor liver transplant.

Interleukin 28B genotype

Intervention Type GENETIC

Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)

Liver Donors

Patients who donated part of their liver to a patient suffering from chronic hepatitis C

Interleukin 28B genotype

Intervention Type GENETIC

Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interleukin 28B genotype

Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who received a living donor liver transplant for chronic hepatitis C who are 18 year or older
* Patients who donated part of their liver to patients suffering from chronic hepatitis C. Donors must be 18 years or older